Kiniksa hits 52-week high as Regeneron-partnered lead product drives Q1 beat
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares · PHARMACEUTICAL PREPARATIONS · Now $48.43
+5.7% in 7d after detection
Post-detection moves
1h
—
1d
-1.6%
3d
+2.6%
7d
+5.7%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS